NEOS Investment Management LLC Reduces Stock Position in Insulet Co. (NASDAQ:PODD)

NEOS Investment Management LLC reduced its position in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 44.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,350 shares of the medical instruments supplier's stock after selling 5,047 shares during the quarter. NEOS Investment Management LLC's holdings in Insulet were worth $1,658,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. SBI Securities Co. Ltd. bought a new stake in Insulet in the 4th quarter worth about $36,000. SRS Capital Advisors Inc. raised its holdings in shares of Insulet by 43.1% during the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after purchasing an additional 56 shares during the last quarter. TD Private Client Wealth LLC lifted its position in Insulet by 32.6% during the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock valued at $53,000 after purchasing an additional 56 shares during the period. Friedenthal Financial purchased a new stake in Insulet in the fourth quarter worth approximately $57,000. Finally, Assetmark Inc. grew its position in Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock worth $69,000 after purchasing an additional 246 shares during the period.

Insulet Price Performance

Shares of Insulet stock traded down $19.08 during trading on Thursday, reaching $250.05. 220,907 shares of the stock traded hands, compared to its average volume of 705,239. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $289.46. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The business has a fifty day simple moving average of $270.97 and a two-hundred day simple moving average of $259.47. The company has a market capitalization of $17.56 billion, a price-to-earnings ratio of 43.19, a P/E/G ratio of 3.62 and a beta of 1.29.

Remove Ads

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.00 by $0.15. The business had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. Sell-side analysts expect that Insulet Co. will post 3.92 EPS for the current year.

Insiders Place Their Bets

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now owns 3,231 shares of the company's stock, valued at approximately $888,525. The trade was a 36.10 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the firm's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company's stock, valued at approximately $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company's stock.

Analyst Ratings Changes

Several analysts recently commented on the company. JPMorgan Chase & Co. lifted their price objective on Insulet from $280.00 to $330.00 and gave the stock an "overweight" rating in a report on Thursday, December 12th. TD Cowen boosted their target price on shares of Insulet from $264.00 to $324.00 and gave the company a "buy" rating in a research report on Friday, January 3rd. Wells Fargo & Company increased their price target on shares of Insulet from $305.00 to $322.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Royal Bank of Canada assumed coverage on shares of Insulet in a research report on Thursday, March 6th. They set an "outperform" rating and a $340.00 price objective for the company. Finally, Stifel Nicolaus raised their target price on Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a report on Friday, February 21st. Four research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $292.06.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.